Avalo Therapeutics (AVTX) Projected to Post Earnings on Monday

Avalo Therapeutics (NASDAQ:AVTX) is expected to be issuing its Q4 2024 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($1.07) per share for the quarter.

Avalo Therapeutics Stock Down 6.7 %

AVTX opened at $4.06 on Friday. Avalo Therapeutics has a twelve month low of $4.06 and a twelve month high of $16.00. The firm’s 50-day simple moving average is $6.14 and its 200-day simple moving average is $8.14.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Piper Sandler began coverage on shares of Avalo Therapeutics in a research note on Friday, February 28th. They issued an “overweight” rating and a $48.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $18.00 price objective on shares of Avalo Therapeutics in a report on Thursday, March 20th. HC Wainwright reissued a “neutral” rating on shares of Avalo Therapeutics in a research note on Thursday, March 20th. Jefferies Financial Group started coverage on Avalo Therapeutics in a research note on Tuesday, March 25th. They set a “buy” rating and a $23.00 price target on the stock. Finally, Stifel Nicolaus started coverage on Avalo Therapeutics in a research report on Tuesday, March 25th. They issued a “buy” rating and a $36.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.